Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 8/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13418947 | 0.83 | TSHR (0.47) | TACR1TSHRCA1CA2CA7 | |
| SCHEMBL2503023 | 0.82 | TACR1 (0.50) | TACR1TSHRSLC1A1CA1CA2 | |
| SCHEMBL3123916 | 0.78 | EPHX1 (0.48) | SLC1A1TAAR1 | |
| SCHEMBL3129213 | 0.78 | EPHX1 (0.48) | SLC1A1TAAR1 | |
| SCHEMBL3134409 | 0.75 | ANPEP (0.42) | TAAR1 | |
| Hydrochloric Acid SCHEMBL8817784 | 0.74 | TACR1 (0.49) | TACR1TSHRSLC1A1CA1CA2 | |
| SCHEMBL18580070 | 0.74 | TACR1 (0.49) | TACR1TSHRSLC1A1CA1CA2 | |
| SCHEMBL27605151 | 0.73 | TACR1 (0.47) | TACR1TSHRSLC1A1CA1CA2 | |
| SCHEMBL18394417 | 0.73 | TACR1 (0.63) | TACR1TSHRSLC1A1CA1CA2 | |
| SCHEMBL22013212 | 0.73 | TACR1 (0.63) | TACR1TSHRSLC1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1491537-B1 | HYDROXYMORPHOLINONE DERIVATIVE AND MEDICINAL USE THEREOF | SENJU PHARMA CO (JP) | 2010-07-07 | — | — | EP | disclosed |
| US-7223755-B2 | Hydroxymorpholinone derivative and medicinal use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2007-05-29 | — | — | US | disclosed |
| US-20050176704-A1 | Hydroxymorpholinone derivative and medicinal use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176704-A1 | Hydroxymorpholinone derivative and medicinal use thereof | CAPN1, OPRM1, CAPN2 | TACR1 153/4885TSHR 3400/4885SLC1A1 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.